Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report)’s stock price fell 6.8% during mid-day trading on Tuesday after Sanford C. Bernstein downgraded the stock from a market perform rating to an underperform rating. Sanford C. Bernstein now has a $8.30 price target on the stock, down from their previous price target of $11.90. Summit Therapeutics traded as low as $10.82 and last traded at $11.0190. 2,758,735 shares traded hands during trading, a decline of 42% from the average daily volume of 4,719,630 shares. The stock had previously closed at $11.82.
Other equities research analysts also recently issued reports about the stock. Stifel Nicolaus cut their price target on shares of Summit Therapeutics from $45.00 to $38.00 and set a “buy” rating for the company in a report on Friday, July 24th. Guggenheim reaffirmed a “buy” rating on shares of Summit Therapeutics in a research note on Wednesday, August 26th. Summit Redstone set a $25.00 target price on shares of Summit Therapeutics in a report on Wednesday, September 9th. Morgan Stanley lowered shares of Summit Therapeutics to an “outperform” rating in a research note on Tuesday, September 29th. Finally, HC Wainwright reissued a “buy” rating on shares of Summit Therapeutics in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Summit Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.10.
View Our Latest Report on SMMT
Institutional Investors Weigh In On Summit Therapeutics
Summit Therapeutics Stock Down 1.6%
The firm’s fifty day simple moving average is $16.02 and its 200 day simple moving average is $16.07.
Summit Therapeutics Company Profile
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.
Further Reading
- Five stocks we like better than Summit Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
